ZYNE — Zynerba Pharmaceuticals Share Price
Last trade - 00:00- $97.69m
- $22.04m
- 46
- 39
- 21
- 29
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.2% | ||
| Return on Equity | -52.45% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.01 | n/a | 0.09 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. The Company is focused on the development of pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and a heterogeneous group of rare epilepsies known as developmental and epileptic encephalopathies (DEE). Its lead product candidate, Zygel (ZYN002 CBD Gel) is a cannabidiol (CBD) gel for FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare epilepsies known as DEE. Its clinical program for Zygel includes clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS, ASD and 22q and the reduction of seizures and the treatment of associated symptoms in patients with DEE syndromes.
Directors
- Armando Anido CHM (63)
- Terri Sebree PRE (63)
- James Fickenscher CFO (57)
- Suzanne Hanlon VPR (64)
- Brian Rosenberger VBD (52)
- Warren Cooper LED (68)
- John Butler IND (56)
- William Federici IND (61)
- Daniel Kisner IND (74)
- Kenneth Moch IND (66)
- Pamela Stephenson IND (53)
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- January 31st, 2007
- Public Since
- August 5th, 2015
- No. of Shareholders
- 49
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 41,217,537
- Address
- 80 W. Lancaster Avenue, Suite 300, DEVON, 19333
- Web
- http://zynerba.com/
- Phone
- +1 4845817505
- Contact
- Peter Vozzo
- Auditors
- KPMG LLP
Latest News for ZYNE
Upcoming Events for ZYNE
Q4 2021 Zynerba Pharmaceuticals Inc Earnings Release
Q1 2022 Zynerba Pharmaceuticals Inc Earnings Release
Similar to ZYNE
4d Pharma
NASDAQ Global Market
89bio
NASDAQ Global Market
Acceleron Pharma
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
FAQ
As of Today at 20:16 UTC, shares in Zynerba Pharmaceuticals are trading at $2.37. This share price information is delayed by 15 minutes.
Shares in Zynerba Pharmaceuticals last closed at $2.37 and the price had moved by -33.8% over the past 365 days. In terms of relative price strength the Zynerba Pharmaceuticals share price has underperformed the S&P500 Index by -43.27% over the past year.
The overall consensus recommendation for Zynerba Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Zynerba Pharmaceuticals does not currently pay a dividend.
Zynerba Pharmaceuticals does not currently pay a dividend.
Zynerba Pharmaceuticals does not currently pay a dividend.
To buy shares in Zynerba Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.37, shares in Zynerba Pharmaceuticals had a market capitalisation of $97.69m.
Here are the trading details for Zynerba Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ZYNE
Based on an overall assessment of its quality, value and momentum Zynerba Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zynerba Pharmaceuticals is $7.50. That is 216.46% above the last closing price of $2.37.
Analysts covering Zynerba Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.97 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zynerba Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -48.16%.
As of the last closing price of $2.37, shares in Zynerba Pharmaceuticals were trading -43.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zynerba Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zynerba Pharmaceuticals' management team is headed by:
- Armando Anido - CHM
- Terri Sebree - PRE
- James Fickenscher - CFO
- Suzanne Hanlon - VPR
- Brian Rosenberger - VBD
- Warren Cooper - LED
- John Butler - IND
- William Federici - IND
- Daniel Kisner - IND
- Kenneth Moch - IND
- Pamela Stephenson - IND